Compare Entegris Inc (ENTG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Tango Therapeutics Inc. — how do they compare? Entegris Inc trades at $145.48 (market cap $23.39B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Entegris Inc is far larger — about 6.3× Tango Therapeutics Inc.'s market cap, and Entegris Inc pays a 0.26% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Tango Therapeutics Inc. for 0 Days on average.
| ENTG | TNGX | |
|---|---|---|
Market Cap | $23.39B | $3.74B |
Volume | 2,918,074 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $184.00 | $32.90 |
52-Week Low | $68.80 | $7.50 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $26.60B | $2.76B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $161.16, up 0.72% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results anticipated. Revenue remains stable around $3.2 billion, while profitability metrics show improvement, though valuation ratios like a P/E of 80.58 appear elevated. Positive sentiment is driven by AI-related semiconductor demand and recent institutional buying.
The outlook is positive given earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. Upside to the $186.56 consensus price target depends on continued execution and market conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
